• CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases
  • CDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functions
  • Rapid, profound, dose-dependent, and durable reductions in serum tryptase observed
  • Well-tolerated at all dose levels
  • First company to demonstrate that neutralizing soluble SCF can selectively inhibit KIT signaling in mast cells